このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Xenon Pharmaceuticals マネジメント
マネジメント 基準チェック /24
Xenon Pharmaceuticals'の CEO はIan Mortimerで、 Mar2018年に任命され、 の在任期間は 6.25年です。 の年間総報酬は$ 10.12Mで、 6.6%給与と93.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.06%を直接所有しており、その価値は$ 1.73M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と3.3年です。
主要情報
Ian Mortimer
最高経営責任者
US$10.1m
報酬総額
| CEO給与比率 | 6.6% |
| CEO在任期間 | 6.3yrs |
| CEOの所有権 | 0.06% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 3.3yrs |
経営陣の近況
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29
Recent updates
We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right
May 29Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$189m |
| Dec 31 2023 | US$10m | US$666k | -US$182m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$164m |
| Mar 31 2023 | n/a | n/a | -US$148m |
| Dec 31 2022 | US$9m | US$595k | -US$126m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$91m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$4m | US$524k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$59m |
| Mar 31 2021 | n/a | n/a | -US$37m |
| Dec 31 2020 | US$2m | US$462k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$28m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$2m | US$421k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$44m |
| Mar 31 2019 | n/a | n/a | -US$42m |
| Dec 31 2018 | US$923k | US$342k | -US$34m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$27m |
| Mar 31 2018 | n/a | n/a | -US$27m |
| Dec 31 2017 | US$945k | US$312k | -US$31m |
報酬と市場: Ianの 総報酬 ($USD 10.12M ) は、 US市場 ($USD 6.82M ) の同規模の企業の平均を上回っています。
報酬と収益: Ianの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Ian Mortimer (48 yo)
6.3yrs
在職期間
US$10,117,829
報酬
Mr. Ian C. Mortimer, M.B.A, C.P.A, C.M.A., has been the Chief Executive Officer and Director at Xenon Pharmaceuticals Inc. since June 03, 2021. He has been an Independent Director at Perimeter Medical Imag...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 6.3yrs | US$10.12m | 0.060% $ 1.8m | |
| Chief Financial Officer | 3yrs | US$3.52m | 0% $ 0 | |
| Executive Vice President of Strategy & Innovation | no data | US$2.37m | 0.011% $ 327.5k | |
| Chief Commercial Officer | 3.8yrs | US$2.76m | 0.0053% $ 156.0k | |
| Chief Medical Officer | 2.8yrs | US$3.58m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 1.6yrs | US$3.55m | データなし | |
| Executive Vice President of Human Resources | 4.8yrs | データなし | データなし | |
| Executive Vice President of Drug Discovery | 8.3yrs | US$545.00k | データなし | |
| Executive Vice President of R&D Operations | 3.8yrs | データなし | データなし |
3.8yrs
平均在職期間
54.5yo
平均年齢
経験豊富な経営陣: XENEの経営陣は 経験豊富 であると考え られます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 3yrs | US$10.12m | 0.060% $ 1.8m | |
| Independent Director | less than a year | US$770.91k | データなし | |
| Independent Director | 20.4yrs | US$560.09k | 0.038% $ 1.1m | |
| Independent Director | 3.6yrs | US$559.58k | 0% $ 0 | |
| Independent Director | 9.1yrs | US$561.42k | 0.0027% $ 78.0k | |
| Independent Chairman | 7.8yrs | US$588.37k | 0.033% $ 974.9k | |
| Independent Director | less than a year | US$770.91k | データなし | |
| Independent Director | 3yrs | US$548.57k | 0% $ 0 |
3.3yrs
平均在職期間
61.5yo
平均年齢
経験豊富なボード: XENEの 取締役会 は 経験豊富 であると考えられます ( 3.3年の平均在任期間)。